BlossomHill Therapeutics (BLSM) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Phathom Pharmaceuticals is the larger company by market cap ($550.9 million vs $527.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | PHAT |
|---|---|---|
| Share price | $16.61 | $6.81 |
| Market cap | $527.95M | $550.94M |
| 1-day change | -3.93% | +0.44% |
| YTD return | — | -58.95% |
| 1-year return | — | -37.18% |
| 5-year return | — | -79.05% |
| Forward P/E | — | 6.33 |
| EPS (TTM) | $-4.70 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $18.31 |
| 52-week low | $15.25 | $6.52 |
| Distance from 52-week high | -40.66% | -62.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +113.12% | +200.29% |
| Average volume | 263.69K | 1.39M |
| Shares outstanding | 31.78M | 80.90M |
| Employees | 69 | 371 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Healthcare · Biotechnology · 69 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Healthcare · Biotechnology · 371 employees
BLSM vs PHAT FAQ
Which is bigger, BlossomHill Therapeutics or Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $550.94M compared with $527.95M for BlossomHill Therapeutics (BLSM).
Are BlossomHill Therapeutics and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.